Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00300027
Status:
TERMINATED
Last Update Posted:
2010-03-02
First Post:
2006-03-06
Brief Title:
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal GI Malignancies
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase I Study to Determine the Safety Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With 5-FluorouracilLeucovorin and Irinotecan or Oxaliplatin for Patients With Advanced or Metastatic Cancer
Status:
TERMINATED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to define the recommended dose of BMS-582664 that could be safely combined with 5-fluorouracil leucovorin and irinotecan FOLFIRI or 5-fluorouracil leucovorin and oxaliplatin FOLFOX chemotherapy regimens in patients with advanced gastrointestinal malignancies and to evaluate the safety profile tolerability pharmacokinetics PK and pharmacodynamics PD of these combinations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None